ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens
ZIVO Bioscience, Inc. (OTCQB: ZIVO) reports favorable results from a 42-day study of its coccidiosis treatment in broiler chickens. The study, conducted with a major global animal health company, showed that ZIVO's non-antibiotic, immune-modulating product significantly improved growth performance and reduced clinical signs of disease when used in combination with existing treatments. Chickens treated with ZIVO's product alongside an ionophore or vaccination achieved feed conversion ratios comparable to healthy, uninfected birds. This demonstrates the product's potential to enhance current treatment options and its standalone treatment capabilities for coccidiosis, a major challenge in poultry production.
ZIVO Bioscience, Inc. (OTCQB: ZIVO) riporta risultati favorevoli da uno studio di 42 giorni sul suo trattamento per la coccidiosi nei polli da carne. Lo studio, condotto con una importante azienda globale nel settore della salute animale, ha mostrato che il prodotto immunomodulatore non antibiotico di ZIVO ha significativamente migliorato le performance di crescita e ridotto i segni clinici della malattia quando utilizzato in combinazione con trattamenti esistenti. I polli trattati con il prodotto di ZIVO insieme a un ionoforo o a una vaccinazione hanno raggiunto rapporti di conversione alimentare paragonabili a quelli di uccelli sani e non infetti. Questo dimostra il potenziale del prodotto di potenziare le opzioni di trattamento attuali e le sue capacitá di trattamento autonomo per la coccidiosi, una sfida significativa nella produzione avicola.
ZIVO Bioscience, Inc. (OTCQB: ZIVO) informa sobre los resultados favorables de un estudio de 42 días sobre su tratamiento para la coccidiosis en pollos de engorde. El estudio, realizado en colaboración con una importante empresa global de salud animal, demostró que el producto inmunomodulador no antibiótico de ZIVO mejoró significativamente el rendimiento de crecimiento y redujo los signos clínicos de enfermedad cuando se usó en combinación con tratamientos existentes. Los pollos tratados con el producto de ZIVO junto con un ionóforo o una vacunación alcanzaron razones de conversión de alimentos comparables a las de aves sanas y no infectadas. Esto demuestra el potencial del producto para mejorar las opciones de tratamiento actuales y sus capacidades de tratamiento independiente para la coccidiosis, un gran desafío en la producción avícola.
ZIVO Bioscience, Inc. (OTCQB: ZIVO)는 육계에서의 코크시디아 치료에 관한 42일간의 연구에서 유리한 결과를 보고했습니다. 주요 글로벌 동물 건강 회사와 함께 진행된 이 연구는 ZIVO의 비항생제 면역 조절 제품이 기존 치료법과 함께 사용할 때 성장 성능을 상당히 개선하고 질병의 임상 징후를 감소시켰음을 보여주었습니다. ZIVO의 제품으로 치료 받은 닭은 이온포르 또는 예방 접종과 함께 사용할 때 건강한 비감염 조류와 유사한 사료 전환 비율을 달성했습니다. 이는 이 제품이 현재 치료 옵션을 향상시키는 잠재성과 코크시디아에 대한 독립 치료 능력이 있음을 보여줍니다. 이는 가금류 생산에서의 주요한 도전 과제입니다.
ZIVO Bioscience, Inc. (OTCQB: ZIVO) rapporte des résultats favorables d'une étude de 42 jours sur son traitement de la coccidiose chez les poulets de chair. L'étude, réalisée en collaboration avec une grande entreprise mondiale de santé animale, a montré que le produit immunomodulateur non antibiotique de ZIVO a considérablement amélioré la performance de croissance et réduit les signes cliniques de la maladie lorsqu'il était utilisé en combinaison avec des traitements existants. Les poulets traités avec le produit de ZIVO, en parallèle avec un ionophore ou une vaccination, ont atteint des ratios de conversion alimentaire comparables à ceux des oiseaux sains et non infectés. Cela démontre le potentiel du produit à améliorer les options de traitement actuelles et ses capacités de traitement autonomes pour la coccidiose, un défi majeur dans la production avicole.
ZIVO Bioscience, Inc. (OTCQB: ZIVO) berichtet über positives Ergebnisse aus einer 42-tägigen Studie zu seiner Coccidiosetherapie bei Broilern. Die Studie, die in Zusammenarbeit mit einem großen globalen Unternehmen im Bereich Tiergesundheit durchgeführt wurde, zeigte, dass das nicht-antibiotische, immunmodulierende Produkt von ZIVO die Wachstumsleistung signifikant verbesserte und klinische Krankheitszeichen verringerte, wenn es in Kombination mit bestehenden Behandlungen verwendet wurde. Hühner, die mit dem Produkt von ZIVO zusammen mit einem Ionophor oder einer Impfung behandelt wurden, erreichten Futternutzungsraten, die mit gesunden, nicht infizierten Tieren vergleichbar sind. Dies zeigt das Potenzial des Produkts, um die aktuellen Behandlungsoptionen zu verbessern und seine eigenständigen Behandlungsmöglichkeiten gegen Coccidiose, eine große Herausforderung in der Geflügelproduktion, aufzuzeigen.
- Favorable results from 42-day study on coccidiosis treatment
- Significant improvements in growth performance and reduced clinical signs of disease
- Feed conversion ratios comparable to healthy, uninfected birds when used with existing treatments
- Potential to enhance current treatment options and standalone treatment capabilities
- Study funded by major global animal health company, indicating industry interest
- None.
The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds challenged with the coccidiosis-causing parasite, Eimeria, while comparing administration of ZIVO’s product alone or in combination with either an ionophore-based treatment or a coccidiosis vaccine versus birds treated with the ionophore or vaccination alone. Uninfected/untreated healthy birds and infected/untreated birds served as negative and positive disease controls, respectively.
In this study, broiler chickens infected with coccidiosis and treated with ZIVO’s product in combination with an anticoccidial ionophore or vaccination exhibited statistically significant improvements in both growth performance (as measured by feed conversion ratio, FCR) and clinical signs of disease (as measured by intestinal lesion scores), compared with chickens that received only the ionophore or vaccine. With respect to FCR over the 42-day grow-out period, groups treated with ZIVO’s product in combination with either the ionophore or vaccination performed on par with the healthy, uninfected control group.
“We are delighted to report favorable findings from this new study that confirm the effectiveness of our product to support poultry health and productivity in the presence of coccidiosis. These results further demonstrate the versatility of our product candidate not only because of its ability to enhance currently available treatment options, but also because of its standalone treatment potential as validated in numerous prior studies. Maintaining feed conversion ratios comparable to uninfected birds is a notable finding that underscores the value our product offers the poultry industry,” said John Payne, Chairman and CEO of ZIVO Bioscience.
“Coccidiosis is one of the most challenging and costly diseases in poultry production, and the ability to improve outcomes using our product in combination with existing interventions represents a potential breakthrough in disease management. We look forward to advancing our discussions global animal health companies in preparation for commercial markets,” he added.
About Coccidiosis
Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, and as indicated by a 2020 study, the estimated annual costs are approximately
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
Forward Looking Statements
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected time frame for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
_________________________
i Blake, D.P., Knox, J., Dehaeck, B. et al. Re-calculating the cost of coccidiosis in chickens. Vet Res 51, 115 (2020). https://doi.org/10.1186/s13567-020-00837-2
View source version on businesswire.com: https://www.businesswire.com/news/home/20240823637788/en/
ZIVO Bioscience
Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130
kmarchiando@zivobioscience.com
LHA Investor Relations
Tirth T. Patel
(212) 201-6614
tpatel@lhai.com
Source: ZIVO Bioscience, Inc.
FAQ
What were the results of ZIVO's 42-day coccidiosis treatment study in broiler chickens?
How does ZIVO's coccidiosis treatment compare to existing options for broiler chickens?
What is the significance of ZIVO's coccidiosis treatment for the poultry industry?
Who funded ZIVO Bioscience's (OTCQB: ZIVO) latest coccidiosis treatment study?
